Blueprint Medicines (BPMC) PT Raised to $105 at Barclays
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 11/4/2026
- Wall St futures jump as Democrats sweep midterms
- CVS Health plans to split into two public companies by 2028
- UBS starts bullish coverage on Ferrari Group on luxury logistics growth
- Citi cuts Adobe rating on ’rising risk of a hard reset’
- Apple shares slip amid guidance for tightening margins, slowing services growth
Tweet
Share
E-mailGet Alerts BPMC Hot Sheet
Price: $129.46 --0%
Rating Summary:
11 Buy, 18 Hold, 0 Sell
Rating Trend: = Flat
Today's Overall Ratings:
Up: 15 | Down: 20 | New: 12
Rating Summary:
11 Buy, 18 Hold, 0 Sell
Rating Trend: = Flat
Today's Overall Ratings:
Up: 15 | Down: 20 | New: 12
Join SI Premium – FREE
Barclays analyst Peter Lawson raised the price target on Blueprint Medicines (NASDAQ: BPMC) to $105.00 (from $75.00) while maintaining a Equalweight rating.
You May Also Be Interested In
- Citi Downgrades Bank Rakyat Indonesia Persero Tbk PT (BBRI:IJ) (BKRKF) to Neutral
- Damai Entertainment Holdings (1060:HK) PT Lowered to HK$0.64 at Citi
- Globalwafers Co Ltd. (6488:TT) PT Lowered to NT$920 at Citi
Create E-mail Alert Related Categories
Analyst PT ChangeSign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
